Although PAK4 is a potential therapeutic target for ALS, persistent expression of it in the spinal cord after gene therapy might contribute to tumorigenesis because PAK4 is a potent oncogene. The gene discussed is PAK4; the disease is amyotrophic lateral sclerosis.